A RIKEN-led research team has unraveled the molecular details of a key mechanism of the immune system in the gut. The work opens the way to new possibilities for developing versatile, inexpensive vaccines that are swallowed, rather than injected.
“The description of this molecular pathway fills a gap in our understanding of the immune response of the digestive system,” says team leader Hiroshi Ohno. “And it provides molecular targets for compounds taken orally, and therefore offers the hope of an easy-to-administer, cost-effective weapon against infectious diseases and allergies.”
The mouth is the most significant entry point into the body for pathogens, allergens and poisons. Most of what comes into the body through the mouth moves through the digestive system. As a result, the lining of the gut houses the largest part of the entire immune system. It protects the body from disease organisms and foreign particles by secreting vast amounts of antibodies in the form of Immunoglobulin A.
Antibodies combine with, neutralize and mark out their targets, known as antigens, for future attack by other parts of the immune system. In order to form antibodies targeting specific foreign particles or organisms in the digestive system, the antigens are presented to immature dendritic cells in Peyer’s patches—organized bodies of immune system tissue found beneath the epithelial cells that line the gut. It has long been suspected that specialized microfold or M cells (Fig. 1) in the epithelium are involved with the process of moving such antigens from the gut cavity to the immune system cells underneath. Until now, however, the molecular details of the process have remained a mystery.
Using the latest techniques of micro-dissection, microarray analysis, staining, microscopy and molecular genetics to investigate, Ohno and colleagues from the RIKEN Research Center for Allergy and Immunology, Yokohama, collaborated with biologists from Yokohama City University, several other Japanese universities and Stanford University in the US.
They uncovered a particular receptor molecule on M cells that stimulates the immune response by binding to a protein on the hair-like projections or pili of bacteria such as Escherichia coli and Salmonella1. The epithelial M cells engulf foreign bodies in the gut cavity, surrounding them with the cell membrane. These membrane-sealed packages or vesicles are then passed through the body of the M cell to waiting immune system cells in a pocket on the underside (Fig. 2).
The researchers speculated that the M cells may have specific molecular receptors to bind to antigen targets. So, working in mice, Ohno and colleagues used the analytical technique known as microarray technology to scan the genome for receptor molecules specific to M cells. Glycoprotein 2 (GP2) was one such molecule and the microarray analysis showed it was highly associated with epithelium close to Peyer’s patches. When they stained both GP2 and M cells, they discovered that not only was GP2 restricted to M cells on Peyer’s patches in the gut, but that it was also found on M cells associated with immune system tissues in other parts of the body in humans as well as mice. In fact, GP2 is a universal marker for M cells.
Moving in closer, the researchers employed electron microscopy to determine where GP2 was distributed on the M cells. They found it was localized on the membrane facing the gut cavity. By using an antibody that binds only to GP2, they discovered that some was incorporated into vesicular structures in the body of the M cells. This provided further evidence that the receptors were involved in the mechanism for transporting antigens to the immune system cells beneath.
Profiling glycoprotein 2
The next step was to determine what compound or compounds linked to the GP2 receptor. By assessing the structure of GP2, the researchers discovered that it resembles a protein in the kidney that binds to pathogenic E. coli bacteria. Thus, they reasoned that GP2 might also be associated with bacteria in the gut.
Ohno and colleagues then experimented by mixing GP2 with E. coli, and found that it bound to the protein FimH on the bacterial pili. In fact, GP2 binds only to bacteria that carry FimH, and not to bacteria that lack this protein, such as Pseudomonas and Listeria.
Using an intact mouse intestine, the researchers tracked E. coli expressing green fluorescent protein. GP2 accumulated around the bacteria, which then could be followed moving inside the M cells. More than 90% of the bacteria transported through the M cells are captured by dendritic cells. They also showed that this process was severely hampered in E. coli lacking FimH or mice lacking GP2.
Fortified by FimH
Finally, the research team tested the ability of bacteria with and without FimH to induce the immune response in mice. They used a particular type of Salmonella modified to carry a fragment of inactivated toxin used as an antigen in tetanus vaccines. Those bacteria carrying FimH stimulated a much stronger immune response than those without, which the team showed was not the result of any inherent deficiency in the mouse immune system.
“It is reasonable to assume there are other molecules on the M-cell surface responsible for binding and uptake of bacteria lacking FimH,” Ohno says. “This is one of the projects we are now working on. Another is to screen for small compounds that bind tightly to GP2. We can then use these molecules to target to GP2 on M cells in an effort to develop efficient oral vaccines.”
Hase, K., Kawano, K., Nochi, T., Pontes, G.S., Fukuda, S., Ebisawa, M., Kadokura, K., Tobe, T., Fujimura, Y., Kawano, S., et al. Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response. Nature 462, 226–232 (2009).
Hiroshi Ohno was born in Tokyo, Japan, in 1958. He graduated from the School of Medicine, Chiba University, in 1983, and obtained his PhD in 1991 from the same university. He then became an assistant professor of the School of Medicine, and was promoted to associate professor in 1997. He spent three years from 1994 to 1997 as a visiting scientist at the National Institute of Child Health and Human Development, National Institutes of Health in the USA. In 1999, he became a full professor at the Cancer Research Institute of Kanazawa University. He joined the RIKEN Research Center for Allergy and Immunology as team leader in 2002, where his research focuses on mucosal immunology, and in particular the role of epithelial cells in the development of the mucosal immune system, mucosal antigen uptake and initiation of mucosal immune responses.
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering